31 completed, 7 terminated, 4 unknown, 1 active not recruiting. 14 Phase 2, 11 Phase 1, 5 Phase 3, 4 Phase 4, 2 Not applicable.
Follow Hepatitis C Infection: new trials by email Literature Review of Hepatitis C Infection trials Research Report on Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of HCV Care and Treatment for HIV-HCV Co-infected Patients in Decentralised Areas in Vietnam Blood samples - HIV Infection, Hepatitis C Infection | Unknown | Institut Pasteur | 400 | 2024-05-01 | 2024-03-06 | |
| Efficacy and Safety of Coblopasvir Hydrochloride Capsules Combined With Sofosbuvir Tablets for the Treatment of Chronic HCV Infection: A Prospective, Multi-center Real-world Study. Hepatitis C Infection | Unknown | Beijing Tsinghua Chang Gung Hospital | 450 | 2022-11-01 | 2022-11-01 | |
| Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection Glecaprevir/Pibrentasvir (G/P) - Hepatitis C Infection, HIV Infection | Phase 2 | Completed | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | 45 | 2019-11-20 | 2024-07-11 |
| Feasibility of Implementing a Cohort of People Living With Hepatitis C in Vietnam Clinical examination - Hepatitis C Infection | Completed | Centre Hospitalier Universitaire de Nīmes | 300 | 2018-09-13 | 2026-06-17 | |
| Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks ombitasvir/paritaprevir/ritonavir 8 weeks, dasabuvir 8 weeks - Hepatitis C Infection | Completed | Hepa C | 200 | 2017-02-20 | 2018-05-21 | |
| Pembrolizumab (MK-3475) in Hepatocellular Carcinoma Elbasvir/Grazoprevir, Laboratory Biomarker Analysis, Pembrolizumab - BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 15 | 2016-12-09 | 2025-07-15 |
| Hepatitis C Infection in World Trade Center Responders Hepatitis C Infection | Completed | Icahn School of Medicine at Mount Sinai | 3906 | 2016-12-01 | 2019-02-04 | |
| DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis - Chronic Hepatitis, Hepatitis C Infection | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 33 | 2016-06-06 | 2026-09-11 |
| A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults ombitasvir/paritaprevir/ritonavir, dasabuvir - Hepatitis C Infection, Hepatitis C Virus | Phase 3 | Completed | AbbVie | 166 | 2015-11-24 | 2021-07-30 |
| A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals AdCh3NSmut1, MVA-NSmut - Hepatitis C Infection | Phase 1 | Completed | University of Oxford | 20 | 2015-07-21 | 2018-10-11 |
| Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality Hepatitis C Infection | Completed | Icahn School of Medicine at Mount Sinai | 150 | 2015-06-01 | 2019-02-26 | |
| Effects of Persistent Innate Immune Activation on Vaccine Efficacy Recombivax - Hepatitis C Infection | Phase 4 | Terminated | Rockefeller University | 24 | 2015-05-08 | 2020-03-04 |
| Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors Laboratory Biomarker Analysis, Navitoclax, Pharmacological Study - Cirrhosis, Hepatitis B Infection | Phase 1 | Completed | National Cancer Institute (NCI) | 29 | 2015-01-30 | 2024-11-22 |
| Safety Study of the Aethlon Hemopurifier Affinity plasmapheresis - End Stage Renal Disease, Hepatitis C Infection | Not applicable | Terminated | Aethlon Medical Inc. | 8 | 2014-12-01 | 2017-03-14 |
| A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir Daclatasvir, Asunaprevir - Hepatitis C Infection | Phase 1 | Completed | Bristol-Myers Squibb | 88 | 2014-12-01 | 2015-02-24 |
| Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt 2 DAA, RBV - HCV, Hepatitis C Infection | Phase 3 | Completed | AbbVie | 160 | 2014-11-04 | 2021-07-30 |
| A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv - Hepatitis C Infection, HIV Infection | Phase 1 | Completed | University of Oxford | 33 | 2014-10-01 | 2018-10-11 |
| HCV-HIV Co-infected Patient Cohort in Thailand Peg-interferon + ribavirin under HIV physician supervision - Hepatitis C Infection, HIV | Phase 4 | Completed | Institut de Recherche pour le Developpement | 18 | 2014-08-01 | 2019-06-03 |
| Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study Sofosbuvir, Ribavirin, and Stribild - Hepatitis C Infection, HIV Infection | Phase 4 | Completed | Saint Michael's Medical Center | 10 | 2014-07-01 | 2016-08-04 |
| Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) Grazoprevir + Elbasvir, Ribavirin - Hepatitis C Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 420 | 2014-06-05 | 2021-02-05 |
Showing 20 of 44. Sign in to see all of them.
Hepatitis C (44) · HIV Infections (8) · Carcinoma, Hepatocellular (5) · Fibrosis (3) · Hepatitis B (2) · Kidney Failure, Chronic (2) · Adenoviridae Infections (1) · Bronchiolitis Obliterans Syndrome (1) · Depression (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Inflammation (1) · Liver Cirrhosis (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Blood-Borne Infections (44) · Communicable Diseases (44) · Digestive System Diseases (44) · Flaviviridae Infections (44) · Hepatitis (44) · Infections (44) · Liver Diseases (44) · RNA Virus Infections (44) · Hepatitis, Viral, Human (43) · Virus Diseases (43) · Urogenital Diseases (10) · Immune System Diseases (9) · Genital Diseases (8) · Immunologic Deficiency Syndromes (8) · Lentivirus Infections (8)
Ribavirin (13) · peginterferon alfa-2a (6) · daclatasvir (5) · peginterferon alfa-2b (3) · Hepatitis B Vaccines (2) · N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (2) · Sofosbuvir (2) · asunaprevir (2) · dasabuvir (2) · elbasvir-grazoprevir drug combination (2) · nitazoxanide (2) · ombitasvir (2) · paritaprevir (2) · telaprevir (2) · 8-cyclohexyl-N-((dimethylamino)sulfonyl)-1,1a,2,12b-tetrahydro-11-methoxy-1a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)cycloprop(d)indolo(2,1-a)(2)benzazepine-5-carboxamide (1)
Bristol-Myers Squibb (6) · AbbVie (2) · Icahn School of Medicine at Mount Sinai (2) · Merck Sharp & Dohme LLC (2) · National Cancer Institute (NCI) (2) · University of Oxford (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Aethlon Medical Inc. (1) · Arrowhead Regional Medical Center (1) · Beijing Tsinghua Chang Gung Hospital (1) · Biotest Pharmaceuticals Corporation (1) · Centre Hospitalier Universitaire de Nīmes (1) · Chang Gung Memorial Hospital (1) · Chao Family Comprehensive Cancer Center (1) · Columbia University (1)
United States (23) · Japan (3) · Puerto Rico (3) · France (2) · United Kingdom (2) · Vietnam (2) · Australia (1) · Brazil (1) · China (1) · Ireland (1) · Netherlands (1) · New Zealand (1) · Spain (1) · Switzerland (1) · Taiwan (1)
Ahmed O Kaseb, MD (1) · Alexander Thompson, MD, PhD (1) · Andrea D Branch, PhD (1) · Andrew J Muir, MD (1) · Arthur Y. Kim, MD (1) · Brian A Costello (1) · Charles Rice, PhD (1) · Colm Bergin, Prof (1) · David Burger, PharmD, PhD (1) · David Gorard, Dr (1) · David Wyles, MD (1) · Didier Laureillard, MD (1) · Donald Mitchell (1)
PMID 20936979, PMID 22075088, PMID 22170543, PMID 22714001, PMID 23152368, PMID 23178977, PMID 23183526, PMID 24041792, PMID 24468783, PMID 24631093, PMID 25378645, PMID 26130251, PMID 26683763, PMID 27720838, PMID 28193518, PMID 29404492, PMID 29461687, PMID 30160363, PMID 30713538, PMID 33317695, PMID 40736252
2009 (1), 2014 (1), 2015 (1), N01CN00042 (1), N01CN35160 (1), P30CA015083 (1), U19AI111825 (1), UM1AI068636 (1), UM1CA186686 (1)